Adial Pharmaceuticals (ADIL) Notes Payables (2017 - 2022)

Adial Pharmaceuticals (ADIL) posted Notes Payables of $492000.0 for Q4 2022, up 1540.0% sequentially from $30000.0 in Q3 2022.

Adial Pharmaceuticals (ADIL) Notes Payables (2017 - 2022) Analysis & Trends

Adial Pharmaceuticals has reported Notes Payables for 4 years, with the latest figure at $492000.0 in Q4 2022.

Quarterly Notes Payables changed N/A year-over-year to $492000.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $492000.0 (changed N/A YoY) and the FY2022 annual result came in at $492000.0, changed N/A from the prior year.
Notes Payables grew to $492000.0 in Q4 2022 per ADIL's latest filing, from $30000.0 in the prior quarter.
Over five years, Notes Payables peaked at $492000.0 in Q4 2022 and troughed at $752.0 in Q2 2018.
A 3-year average of $145368.0 and a median of $30000.0 in 2022 frame the typical range for Notes Payables.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.90 Bn	131.05 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.10 Bn	78.11 Bn	3.93 Bn
3	Argenx Se	65.56 Bn	60.37 Bn	1.37 Bn
4	Moderna	55.82 Bn	50.68 Bn	52.00 Mn
5	BeOne Medicines	42.14 Bn	37.04 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.67 Bn	28.36 Bn	992.69 Mn
7	BioNTech SE	27.74 Bn	9.35 Bn	668.28 Mn
8	Insmed	27.53 Bn	26.37 Bn	358.27 Mn
9	Royalty Pharma	27.38 Bn	26.54 Bn	-
10	Adial Pharmaceuticals	27.94 Mn	27.94 Mn	-

Download Data